AngioDynamics

AngioDynamics recently announced the sale of its PICC and Midline product portfolios to Spectrum Vascular for up to $45 million in cash.

The company PICC, Midline and tip location products contributed approximately $43.5 million in annual sales during AngioDynamics’ fiscal year 2023. The transaction consists of $34.5 million paid at closing, an earnout related to sales of the divested products over the next two years equal to $5.5 million and a milestone payment of $5 million paid upon final transfer of the manufacturing of the divested products to a third-party manufacturer.

The company also announced it discontinued the sale of its Uniblate and Starburst Radio Frequency products and Syntax support catheter products.

“Today’s divestiture is another significant milestone in our transformation and supports our focus on driving increased penetration of our medtech platforms in high-growth markets. It builds upon the divestiture of our Dialysis and Bi…

AngioDynamics (Nasdaq:ANGO) shares ticked up before hours on second-quarter results that topped the consensus forecast.

Shares of ANGO rose 7.6% to $14.65 apiece before the market opened.

The Latham, N.Y.–based peripheral artery disease (PAD) treatment developer posted losses of $8.5 million. That amounts to losses of 21¢ per share on sales of $85.4 million for the three months ended Nov. 30, 2022.

AngioDynamics recorded a slight bottom-line slide further into the red on sales growth of 9.1%.

Adjusted to exclude one-time items, earnings per share totaled 1¢. That falls 2¢ ahead of projections on Wall Street. Analysts expected sales of $84.33 million.

The company’s medtech business sales grew 29.7% year-over-year. AngioDynamics attributed that growth to drivers including sales of its Auryon peripheral atherectomy platform. Medical device sales increased 2.6% year-over-year to $60.9 million.

“We drove strong performance during th…

AngioDynamics (Nasdaq:ANGO) shares took a hit today on first-quarter results that came up shy of the consensus forecast.

Shares of ANGO dipped 12.6% at $18.84 apiece as the market opened today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.5%.

The Latham, N.Y.-based peripheral artery disease (PAD) treatment developer posted losses of $13 million, or 33¢ per share. It registered sales of $81.5 million for the three months ended Aug. 31, 2022, for an 86.5% bottom-line slide deeper into the red on sales growth of 5.9%.

Adjusted to exclude one-time items, losses per share were 6¢, 4¢ behind Wall Street, where analysts were looking for sales of $83.4 million.

The company reported net medtech sales of $22.8 million. Growth drivers there included the Auryon peripheral atherectomy platform, the thrombus management platform and the NanoKnife irreversible electroporation platfor…

AngioDynamics (Nasdaq:ANGO) shares ticked up today on third-quarter results that were mixed compared to the consensus forecast.

The Latham, N.Y.-based peripheral artery disease (PAD) treatment developer posted losses of nearly $5 million, or 13¢ per share, on sales of $74 million for the three months ended Feb. 28, 2022, for a 40% bottom-line slide on sales growth of 3.9%.

Adjusted to exclude one-time items, earnings per share were 3¢, 4¢ ahead of Wall Street, where analysts were looking for sales of $76.3 million.

We are proud of our team’s ability to drive continued growth in our business during the third quarter while operating amid macro-related supply chain disruptions, procedural volume challenges and ongoing inflation, particularly in December and January,” AngioDynamics President and CEO Jim Clemmer said in a news release. “Even as we started to see benefits of our capacity enhancement initiatives, we saw our backlog increase during o…

AngioDynamics (NSDQ:ANGO) shares took a hit today on second-quarter results that were mixed compared to the consensus forecast.

The Latham, N.Y.-based peripheral artery disease (PAD) treatment developer posted losses of $8.4 million, or 21¢ per share, on sales of $78.3 million for the three months ended Nov. 30, 2021, nearly doubling its losses from the same period last year despite sales growth of 7.6%.

Adjusted to exclude one-time items, earnings per share were 2¢, coming in just behind EPS projections of $0 on Wall Street, where analysts were looking for sales of $77.9 million.

“We are pleased with our continued strong revenue growth as our team navigates this dynamic macro environment and manages through persistent COVID headwinds,” AngioDyanmics President & CEO Jim Clemmer said in a news release. “Revenue growth this quarter was driven by our medtech platforms, particularly our atherectomy and thrombectomy portfolios.”

AngioDynamics…

AngioDynamics (NSDQ:ANGO) shares ticked up this morning on fourth-quarter results that beat the consensus revenue forecast.

The Latham, N.Y.-based peripheral artery disease (PAD) treatment developer posted losses of -$19.5 million, or -51¢ per share, on sales of $76.8 million for the three months ended May 31, 2021, for an 87.6% bottom-line gain on sales growth of 31.7%.

Adjusted to exclude one-time items, earnings per share were even at $0, equaling the projections made on Wall Street, where analysts were looking for sales of $72.7 million.

“The AngioDynamics team demonstrated excellent performance, resilience, and strong execution in what was a uniquely challenging year. We saw the pressure from COVID-19 gradually alleviate over the course of the year, and our business is now trending close to normalized run rates. During fiscal 2021, we took significant steps forward in our transformation into a growth-oriented, technology-driven company, building on …

AngioDynamics (NSDQ:ANGO) posted fourth-quarter results that missed the consensus forecast on Wall Street.

The company reported losses of -$156.1 million, or -$4.10 per share, on sales of $58.3 million for the three months ended May 31, for a sales loss of -18.1% compared with Q4 2019.

Adjusted to exclude one-time items, earnings per share were -6¢, 8¢ ahead of The Street, where analysts were looking for sales of $58.3 million.

“Our fourth-quarter sales were impacted by the deferral of elective procedures associated with COVID-19, and we adjusted accordingly throughout the quarter to minimize the impact of the global pandemic on our business,” president and CEO Jim Clemmer said in a news release.

“Despite these temporary challenges, the underlying long-term fundamentals of our business remain intact, and we intend to continue investing strategically in our key growth platforms like Auryon, NanoKnife, and AngioVac. The steps that we took to manage …